Results 61 to 70 of about 16,883 (239)

Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini

Open Forum Infectious Diseases, 2023
Birth defect surveillance in Eswatini in 2020–2021 identified 0.80% defects (197/24 599 live and stillborn infants). Neural tube defect (NTD) prevalence was 0.08%, 0.08%, and 0.15% for 4902 women on dolutegravir preconception, 17 285 HIV-negative women ...
M. Gill, Philisiwe N. Khumalo, C. Chouraya, Mthokozisi Kunene, Futhi Dlamini, H. Hoffman, A. Scheuerle, B. Nhlabatsi, Wiseman Mngometulu, Ntombikayise Dlamini-Madlopha, Nompumelelo Mthunzi, L. Mofenson   +11 more
semanticscholar   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study

Heliyon
Background: Recently, dolutegravir-based therapy has become the first-line treatment when compared to others. However, dolutegravir-associated side effects in the liver and levels of efficacy haven't been addressed yet in underdeveloped countries such as
Enyew Fenta Mengistu, Dr Tabarak Malik, Meseret Derbew Molla, Adane Adugna, Mohammed Jemal   +4 more
doaj   +1 more source

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.

PLoS ONE, 2020
ObjectivesAging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity.
Martine Auclair, Anne-Claire Guénantin, Soraya Fellahi, Marie Garcia, Jacqueline Capeau   +4 more
doaj   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS (London)
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy.
C. Orkin, A. Antinori, Jürgen K. Rockstroh, Santiago Moreno-Guillén, C. Martorell, J. Molina, Adriano Lazzarin, F. Maggiolo, Y. Yazdanpanah, Kristen N. Andreatta, Hailin Huang, J. Hindman, Hal Martin, A. Pozniak   +13 more
semanticscholar   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

Journal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo, Benson Issarow, Salama Fadhil, Grace Ruselu, Ponsiano Fabian, Ayubu Garbindi, Robert N. Peck, Kathy Baisley, Saidi Kapiga, Ana C. Krieger   +9 more
wiley   +1 more source

Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest Ethiopia, 2021

HIV/AIDS
Background Long-term use of antiretroviral therapy, especially dolutegravir and boosted-atazanavir, raises concerns about cardiovascular disease. Thus, this study aimed to assess lipid profiles, blood glucose, and high-sensitivity C-reactive protein ...
Nuredin Chura Waritu, S. K. P. Nair, Bihonegn Birhan, Tesfaye Adugna, G. Awgichew, Mohammed Jemal   +5 more
semanticscholar   +1 more source

High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam

Scientific Reports, 2023
To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up since 2006, and in 2019, the country shifted to regimen including dolutegravir as a default first line.
G. Bwire, Beatrice Godwin Aiko, I. Mosha, M. Kilapilo, Alli Mangara, Patrick Kazonda, J. P. Swai, Omary Swalehe, Michael R. Jordan, J. Vercauteren, D. Sando, David Temba, A. Shao, Wilhellmuss I Mauka, C. Decouttere, N. Vandaele, Raphael Zozimus Sangeda, J. Killewo, A. Vandamme   +18 more
semanticscholar   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source